RBC Capital analyst Luca Issi initiated coverage of Moderna with an Outperform rating and $200 price target. The "COVID cliff" and its near-term impact on the profit & loss statement is "well appreciated," said the firm, which adds that the company’s RSV vaccine data was "impressive" and contends that Moderna can differentiate by bundling this offering with its COVID vaccine.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on MRNA:
- Moderna, Pfizer: Top mRNA Innovator Stocks are Oversold
- Moderna price target lowered to $200 from $225 at Deutsche Bank
- SVB downgrades Moderna to Underperform as COVID boom reverses
- Moderna downgraded to Underperform from Market Perform at SVB Securities
- Moderna Earnings Update: Did it Beat Estimate Forecasts?